• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

    2020-10-22 04:30:58AnujBohraQuratAlAinRizviCharlotteYuenYuKeungAbhinavVasudevanDanielvanLangenberg
    World Journal of Gastroenterology 2020年36期
    關(guān)鍵詞:大伙

    Anuj Bohra, Qurat-Al-Ain Rizvi, Charlotte Yuen Yu Keung, Abhinav Vasudevan, Daniel R van Langenberg

    Abstract

    Key Words: Inflammatory bowel disease; Infliximab; Safety; Cost; Therapy; Drug reaction

    INTRODUCTION

    Infliximab is a biologic monoclonal IgG antibody against tumour necrosis alpha (anti-TNF). It is a highly effective induction and maintenance treatment for multiple immune-mediated inflammatory disorders, including inflammatory bowel diseases (IBD)[1-3]. Recently in Australia and many countries worldwide, the accessibility of infliximab for indications within IBD has increased, alongside an increasing trend to use accelerated doses and shorter dose intervals to regain and/or achieve remission in certain disease subtypes[4,5]. Hence, despite a growing number of biologic options, many of which are subcutaneously administered, there has still been an increased demand for infliximab infusions over recent years. As a maintenance therapy, infliximab (and other infusion-based biologic agents) are often prescribed on a longterm basis[6-8]. Allocation of funding to resource-intensive infusion centres may not always a priority for hospital administrators, given the traditional hospital model of care is typically focussed on acute inpatient care resulting in continual pressure on infusion centres already at, or near capacity. Additionally, the cost of infusion-based treatment is expensive, with some studies suggesting that the cost of the administering infliximab is approximately 9% to 12% of the total cost of treatment[9,10].

    In an effort to address these capacity and cost issues for infusion centres shortening the infusion time is one potential solution. Rapid infliximab infusions (at typically 30-60 min’ duration per infusion) have been previously identified in IBD and other indications as safe, with the potential for increased capacity yet reduce cost, plus apparently improve patient satisfaction[9,11]. Despite this, with the recent further exponential growth of infusion-based therapies for various chronic diseases, improving efficiencies within infusion centres does not appear sufficient and there is still an imperative to explore further alternatives.

    Home-based infusions are therefore a logical extension from hospital or infusioncentre based infusions and are potentially appealing to both patients and health providers. Home-based infusions of many drug therapies have been demonstrated to be cost-saving and are used in many jurisdictions worldwide[12,13]. However, homebased infliximab poses a challenge given the relatively high rate of infusion reactions, including anaphylaxis and anaphylactoid reactions[14,15], the need to dilute and refrigerate the medication and the two hours required for the infusion and one hour observation period thereafter[16]. Some of these problems can be overcome to allow patients to have their infusions at home. For example, initial therapy can be completed in the hospital to monitor for any reactions and then subsequent infusions can be administered at home. Rapid infusions and home-based infusions of infliximab are currently undertaken at our hospital. The safety of this approach is yet to be comprehensively evaluated. Therefore, we aimed to evaluate the safety of transition from standard hospital-based infliximab infusions to rapid infusions and thence to home-based infusions in a protocolised manner, while also assessing efficiency, cost savings and patient satisfaction with this process.

    MATERIALS AND METHODS

    Patient selection and data collection

    All consecutive patients with confirmed IBD attending two Australian tertiary inflammatory bowel disease centres over a 12-year period from January 2005 to March 2017 who were prescribed infliximab and commenced infusions at the study centres were identifiedviaan IBD database and/or pharmacy dispensing records, then prospectively followed. Inpatients receiving infliximab (for example for acute severe colitis) were excluded from this analysis. All patients underwent standard dosing of infliximab 5 mg per kilogram of body weight for induction at week 0, 2 and 6 followed by maintenance infusions, where dosing/dosage interval may have been altered as per the treating clinician’s discretion, predominantly to address secondary loss of response.

    Data including baseline demographic data, IBD data including disease distribution duration and complications, therapeutic data including adverse drug reactions (ADRs) and location of infliximab administration, were extracted from medical records. The severity of infliximab infusion reactions were graded retrospectively according to the Common Toxicity Criteria (CTC) version 2.0[17]from 1 to 4, with a CTC score of 1-2 graded arbitrarily defined as “mild” and 3-4 as “severe” reactions respectively.

    Inclusion criteria:(1) Aged 18 and above; and (2) Received maintenance therapy infliximab between January 2005 and March 2017 for an IBD indication.

    Exclusion criteria:(1) Less than age 18; (2) Received infliximab for a non – IBD indication; and (3) received infliximab as an inpatient.

    Study outcome measures

    The primary outcome measure in this study was the safety of infliximab infusions, with the standard infusion protocol as per manufacturer’s guidelines as the reference, compared to (1) a rapid infusion protocol; and (2) a rapid infusion protocol administeredviaa home-based service, comparing relative incidence of serious adverse events. Secondary outcomes assessed included the relative cost of infusion centre and home-based infliximab infusions and factors associated with a higher risk of infusion reactions in order to risk stratify patients prior to referral for home-based infusions.

    Initial standard 2-h infusion data was available from patients infused between January 1, 2005 to December 31, 2013, inclusive. Rapid 30-min infliximab infusion data was available from patients infused between January 1, 2014 and March 31, 2017 inclusive and home-based rapid infliximab infusion data was available from patients infused between October 1, 2017 and December 31, 2019 inclusive. In each case, needle to departure times were collected for each patient for time spent in at an infusion centre and compared between the standard and rapid infusion groups.

    Cost analysis

    Moreover, a cost analysis was performed for infusion centre and home-based delivery of infliximab, comprising study centre staff costs (per unit time) and infusion-related consumables (per unit), per infusion. Total infusion time duration was measured from time of cannula insertion to the patient’s time of departure from the infusion centre, or the time of the nurse’s departure from the home setting (i.e., needle to departure time), given these events were accurately recorded in the medical records for all patients.

    Satisfaction and productivity survey relating to rapid/ home-based infusions

    Patients who were transitioned to home-based infusions were asked to complete a survey comprising items assessing their satisfaction regarding rapid infusions compared to standard infusions and rapid infusions administered in infusion centrebasedvshome-based settings (see Appendix). The items included were customised based on feedbackviaqualitative interviews of a subgroup of rapid infusion patients (by investigators DvL and QaR), given no suitable, previously validated surveys were found in the literature. Responses to each item were recorded across a numerical scale from 1 (most negative) to 5 (most positive) with 3 denoted as neutral. Furthermore, the short IBD Questionnaire (sIBDQ), to measure concurrent health-related quality of life and the Work Productivity and Activity Impairment in IBD Questionnaire (WPAIIBD) were also administered to examine perceived effects of rapid infliximab infusions (including home-based) on these domains[18]. Based on the cut-off derived by Swartet al[19], a sIBDQ score of greater than 55 (total 70 indicating excellent quality of life) was deemed to represent a “satisfactory/normal” quality of life[19,20]. Loss of work productivity and daily activity impairment (expressed as a percentage, 100% indicating complete loss/impairment) were derived from the WPAI-IBD as per Reillyet al[20]. The surveys were applied to a seven-day period including a home-based infliximab infusion.

    Infliximab infusion protocols used

    The rapid infusion protocol as applied is shown in Figure 1. Patients underwent their first 3 infusionsviaa standard 2-h infusion protocol, then progressed onto an “accelerated” 1-h infusion for infusion 4-6 if there were no adverse reactions and from the 7thinfusion onwards then received “rapid” infusions over 30 min thereafter assuming no further reactions. ADRs were treated immediately according to severity and only those graded as mild-moderate had a subsequent re-trial of infliximab at the last tolerated infusion rate. A standardised pre-medication regimen of 200 mg intravenous hydrocortisone, 10 mg oral cetirizine and 1 g oral paracetamol was administered to all patients prior to their first three standard infusions and also immediately in the case of ADRs, as per the nursing and/or medical staff’s discretion at the time.

    Subsequently, those who tolerated at least three rapid infusions without ADRs were offered the opportunity to transition their infusion to home-based infusions. Patients with known active psychiatric comorbidities, unsafe (i.e., for visiting nursing staff) or itinerant living conditions and/or previous poor adherence to medications, infusion and/or clinic visits were deemed unsuitable candidates for home-based infusions and were not offered this option.

    Ethics approval

    The Eastern Health Human Research Ethics Committee approved the study as a low risk audit (LR 64/2017), thus informed consent was deemed not required.

    Statistical analysis

    Figure 1 Rapid infliximab infusion protocol. BP: Blood pressure; IV: Intravenous; IFX: Infliximab.

    Comparisons between the infusion groups were performed using non-parametric statistics (assuming non-normal distributions) with medians (ranges) presented and Mann-Whitney tests calculated where appropriate. Proportions were expressed as percentages and compared using Fisher exact tests, including relative risks (RR) of infusion reactions/ADRs which were presented for both per infusion and per patient.

    In order to determine factors potentially associated with the occurrence of one or more infusion reaction(s) to rapid infliximab infusion(s), univariable analyses [expressed as odds ratios (OR) for categorical variables, with 95% confidence intervals displayed] were performed. Then a multivariable logistic regression analysis was conducted with the occurrence of an infusion reaction(s) due to rapid infusion as the dependent variable. Multiple exploratory models were initially undertaken and forced entry models were always used, with the final model chosen on the basis of effect size and goodness of fit of the overall model. All variables with significant or those trending to significance were included in the multivariable analysis plus other putatively important factors were included, such as age and body mass index (BMI) (dichotomised by cut-off < 22 kg/m2representing the lowest quartile in this cohort). Those factors exerting minimal or no effect size within the model (as per standardised B values) were excluded from the final model. APvalue of < 0.05 was deemed to be statistically significant throughout the study.

    RESULTS

    Baseline demographics

    The standard infusion cohort comprised 169 patients who received a total of 2214 infliximab infusions over an 8-year period (2006 to 2013 inclusive) and the rapid infusion cohort comprised 129 patients who received a total of 1461 infusions over a 4-year period (2014-2017 inclusive). Home-based rapid infusions were administered to 32 patients, with a total of 405 infusions over 2.2 years (October 2017 to December 2019 inclusive). The baseline characteristics of the standard and rapid infusion cohorts are represented in Table 1.

    Infliximab infusion ADRs and outcome of rechallenges in standard vs rapid infusion cohorts

    In the standard infusion cohort, a total of 23 patients experienced ADRs directly related to infliximab infusion(s), with 16 of these graded as mild according to CTC. All 16 patients were rechallenged with infliximab of which 15 tolerated the subsequent infusion with the aid of premedications and a slower infusion rate. Seven patients had severe reactions and were not rechallenged.

    In the rapid infusion cohort, 8 patients experienced ADRs due to infliximab, all ofwhich (8/8) were mild as per the CTC. Of these, 7 patients were rechallenged with concurrent premedications administered and all seven tolerated the subsequent infusion; four patients returned to rapid infusions, two remained on accelerated infusions and one returned to the standard infusion protocol. All of the eight patients described had previously documented ADRs to standard protocol infusions.

    Table 1 Baseline characteristics comparing the standard infusion (n = 169) and rapid infusion (n = 129) cohorts

    Hence per infliximab infusion administered, the relative risk (RR) for a mild reaction was 0.8% and 0.7% and for a severe reaction was 0.2% and 0.0% in the standard infusion and rapid infusion cohorts respectively. Per patient, the overall RR for a mild reaction was 10.7% and 7.8% and for a severe reaction 3.0% and 0.0% within the standard and rapid infusion cohorts respectively, as shown in Table 2.

    Moreover, there was a greater likelihood of patients having an infusion reaction (mild or severe) in the standard protocol cohort than patients receiving rapid protocol infusions, RR 3.0, 95%CI (1.2, 7.7),P= 0.02. The median duration from the commencement of infliximab and the first infusion reaction per patient was 17 d (0, 1401) for standard infusions and 637 d (45, 2122) for rapid infusions respectively.

    Factors associated with increased risk of infliximab infusion reactions in this cohort

    A univariable logistic regression analysis was performed on all patients in the cohort who received three or more infliximab infusionsviathe rapid infusion protocol. Factors found to be significantly associated (P< 0.05) and/or trending to significance (0.05 ≤P≤ 0.15) with the occurrence(s) of infliximab ADR/s were then included into a multivariable logistic regression analysis, as shown in Table 3. In summary, a lower BMI (< 22 kg/m2), history of one or more extra intestinal manifestations, longer disease duration (> 3 years) and previous exposure to another biologic were each independently associated with a higher likelihood of infusion reaction(s) to rapid infusions (eachP< 0.05). There was a non-significant trend to a higher risk also with prior episodic and/or a break in maintenance infliximab dosing.

    再說的時候,就說到找一陣了,還是找不到。找不到,摟寶的就直起身,說剛才你們看到了,是萬子吧?他們說,有紅有黑的,應(yīng)該是吧。見大伙認帳,摟寶的跟了句,是八萬吧?這句話,大伙不認帳了。就那么一閃,誰也看不清呀。他想想,也是,那怎么辦呀?大伙說,再找找吧,找到了,我們給錢的,不賴帳的。這次,大伙還幫他找了。找到最后,也沒找到。

    Table 2 Infusion reactions per cohort, type and severity

    Comparison of infusion time/cost and productivity (standard vs rapid infusion cohort)

    Median needle to departure time was significantly higher in the standard protocol than the rapid protocol group [108 (70, 253)vs50 (33, 90) min,P< 0.001] (Figure 2). Based on local costing and consumables, this equated to a median per infusion (per chair) cost of $AUD 49.80 per rapidvs$107.50 per standard protocol infusion (P< 0.001). Hence since inception, rapid infusion protocols resulted in a net cost saving of $AUD 84344 (a net 54% cost reduction) across the whole study centre cohort and follow-up period.

    Transition from infusion centre to home-based rapid infusions: Safety and cost analysis

    The baseline characteristics of the rapid home and rapid infusion centrecohorts are represented in Table 4. 32 patients were transitioned to home-based infusions havingreceived at least three rapid infusions in hospital infusion centres with no history of infusion reaction/s to rapid infusions. In total, 405 infliximab infusions had hitherto been administeredviathe home-based service as of the end of the study follow-up period, with no (0%) reported ADRs. Six patients who subsequently withdrew from the home-based infusion service were due to personal choice (n= 3), change to a different biologic (n= 2) or death (n= 1, unrelated to IBD and/or associated therapies).

    Table 3 Univariable and multivariable logistic regression analyses depicting factors potentially associated with increased likelihood of infliximab infusion reaction/s with a rapid infusion protocol in this cohort (n = 129)

    Table 4 Characteristics of home-based vs infusion centre-based rapid protocol groups

    Moreover, there was no significant difference in needle to departure times between infusion centre and home-based rapid infusions [median 50 (33, 90)vs45 (31, 90) min respectively,P= 0.21] (Figure 2). In turn, there were similar costs (incorporating staffing and consumables) between these groups (median $49.80vs$39.20 per infusion,P= 0.20).

    Figure 2 Needle-to-departure times for standard vs rapid (further subdivided by infusion centre and home based) infliximab protocols.

    Patient satisfaction with home-based infusions: Data from survey

    Of the 32 patients who received infliximabviathe home-based infusion service, 31 (97% response rate) completed the survey as described. 26 of the 31 were in clinical remission as per CDAI < 150 at the time of survey and the median sIBDQ score in responders was 55 (33, 65) with 57% scoring in the “normal” IBD QoL range as per Swartet al[19].

    Only 2 patients (6.4%) reported that their infliximab infusions had a negative impact on their quality of life overall. All 31 (100%) patients preferred the rapid infusionvsthe standard infusion protocol, with 17 patients (54.8%) specifically stating this was due to enhanced convenience (Figure 3).

    14 of the 31 responders (45.2%) disagreed with or were neutral about a preference for home-basedvsinfusion centre-based infusions and 19 (61.3%) found home-based infusions to actually be more inconvenient than those administered in an infusion centre (Figure 3).

    Qualitatively, reasons provided for this included a lack of coordination and communication of the timing of infusions, unforeseen delays in nurse arrival at their home, lack of nursing staff (e.g., due to illness or extra demand) on certain days forcing patients to attend the parent hospital for their infusion(s), lack of sufficiently skilled nurses resulting in difficulties obtaining intravenous access and/or administering infusion at slower rates than prescribed. Additionally, others reported a reluctance to “medicalise” their home and/or have infusions in presence of family members (especially their children) or work colleagues. Also, some patients missed the familiarity of the same nursing staff and the camaraderie enabled by attending the same infusion centre, as many had done, for several years.

    Impact of home-based infusions on work productivity/activity as per survey

    Responses from the WPAI-IBD showed that in the week including when infliximab was infused at home, there was a median of 0 h per week missed from paid work (range 0, 36.7 h), with only 4 (12.9%) reporting a total of one or more hours of work missed in the same week. Also, the median overall work impairment (incorporating both percentage of work hours missed and impairment of work performance) was 10.0% (0, 81.0).

    DISCUSSION

    Figure 3 Results of patient satisfaction survey and preferences regarding standard vs rapid and infusion centre vs home-based infusions.

    This study has demonstrated the safety of rapid 30-min infliximab infusions compared to standard 2-h infusions in patients with IBD. Moreover, by applying a rational stepwise protocol as per Figure 1 culminating in almost 1500 rapid infusions, none of these resulted in severe reactions. Furthermore, of the 8 patients who had mild reaction, 7 were able undertake a re-trial of infliximab on premedication with 6 successfully transitioning back to 30-min rapid infusions. These safety data are consistent with similar protocolised rapid infliximab studies previously[9,21,22], yet are critical to confidently administering infliximab infusions in home-based settings. Otherwise, without stringent protocols, infliximab infusion reactions have been reported in up to 5%-10% of infusions in IBD[15,23], which in our view does not provide adequate assurance of safety for home-based infliximab. Indeed, in this cohort, none of the home-based infusions experienced an adverse reaction as a result of this study centre’s stepwise protocol introducing rapid infusions prior to transitioning to the home.

    In addition, this study is one of the first to elucidate factors associated with a higher risk of adverse reactions with maintenance rapid 30-min infusions, which enables clinicians to further mitigate the risk of adverse reactions on a case-by-case basis. Although infusion reactions to initial infliximab infusions (e.g., with induction or with episodic dosing) are typically attributable to allergic or massive cytokine release pathways, longer term reactions are postulated to be driven primarily by the development of immunogenicity (i.e., antibodies) to infliximab[24]. Accordingly, this study demonstrated that a longer disease duration (> 3 years) was associated with a higher risk of reaction(s), consistent with the known cumulative incidence of antibodies to infliximab in prospective studies[25]. Also, those with prior biologic exposure and/or a break in previous infliximab dosing were found, at least in univariate analysis, to be at higher risk of reaction(s) as has been shown elsewhere[26]. Furthermore, the presence of extraintestinal manifestations, suggestive of a more systemic inflammatory burden and in turn a greater propensity for immunogenicity – for instance due to presence of alternate cytokine-mediated, immune-complex and/or complement mediated processes – appears to be another important risk factor with rapid infusion reactions. Although there was a non-significant trend in univariable analysis to a protective effect of concomitant thiopurine/immunomodulator therapy on infusion reactions, presumably due to their negating effect on antibody development, this did not persist in multivariable analysis. Interestingly, a lower BMI (< 22 kg/m2) was associated with increased risk of rapid infusion reaction(s) despite recent publications showing increased drug clearance and lower anti-TNF drug trough levels seen with higher BMI[27,28]. However, a lower BMI with resultant reduced volume of distribution may in fact result in relatively higher infliximab trough levels and hence greater potential for immunogenicity and thus acute and delayed ADRs. Infliximab drug levels and anti-drug antibodies were not routinely performed in this cohort, so further study into the potential relationship between these factors are needed.

    One of the key benefits of transitioning to 30-min infliximab infusions is that of reduced cost and enhanced productivity for an infusion centre. With introduction of rapid infusions, we demonstrated a halving of needle to departure times per infusion in a real-world context, with attendant cost reduction of 54% across the whole cohort. At an institutional level, this enables a potential doubling of throughput with the same staffing costs for an infusion centre. For the patient and at a societal level, there are additional flow-on benefits such as reduced car parking costs, reduced absence from work and/or family commitments through to improved patient productivity.

    Given the increasing array of intravenous therapies, including infliximab, for chronic diseases leading to infusion centre capacity concerns in many jurisdictions worldwide, transitioning to home-based infusions is a logical solution. However, to ensure the economic sustainability of home-based infusion service, nurses theoretically need to conduct at least 3-4 infusions at patients’ homes per standard 8-h shift, allowing for travel between homes, preparation of infusions and intravenous access, communication with patients,etc. Hence administering infliximab slower than over 30 min is unlikely to be cost-effective in most cases. This study has demonstrated the safe, sustainable administration of infliximab in a home-based setting, subject to appropriate patient selection. Furthermore, this study is one of the first to assess patient satisfaction which overall was high, with 81% highly satisfied or satisfied with home-based infusions. In addition, survey responders reported minimal impact on work or other activitiesviathe WPAI during a typical week that included a homebased infliximab infusion.

    However, the study also revealed previously un-appreciated caveats to implementation of home-based infusions from the patients’ perspective. Almost half of the survey responders were neutral or disagreed that home-based infusions were more convenient, anecdotally for reasons including unforeseen delays to nurse arrival, variable availability of staff to administer infusions, impacts on work and social life and medicalising their home with infusions. These are unintended consequences of transitioning to home-based infusions and pose potential challenges to this model of care which therefore warrant further research and evaluation.

    This study has several limitations, including the retrospective nature of data collection, however the risk of recall bias is somewhat mitigated given this study was primarily an evaluation of protocol and safety in a relatively consistent, homogeneous single centre population. Although the sample size for rapid and standard infusion cohorts were relatively large, the home-based infusion subgroup was small which may have led to selection bias and larger scale evaluation of the latter is required in future. Furthermore, given the large time period across which data was collected and local contemporary practice, we were unable to evaluate the putative relationship between infliximab trough/antibody levels and occurrence of infusion reactions. There was a difference in the rate of psychiatric disorders between the groups. While this is unlikely to have an impact on the results it does reflect that there may be some differences between the groups that was not captured in our demographic data. Prospective validation of the results is required.

    CONCLUSION

    In conclusion, this study comprehensively outlines a safe, patient centred approach to transitioning patients receiving infliximab for IBD from initial standard protocols through to rapid home-based infusions. With careful patient selection, we have demonstrated that the risk of ADRs with home-based infusions is negligible and thus these data are reassuring to patients, clinicians and healthcare providers alike. Whilst there are significant logistical challenges in providing a failsafe, home-based infusion service and ongoing evaluation especially in meeting patient’s care needs is warranted in this regard, most patients were satisfied with this service and the convenience it provides. This study has therefore defined a rigorous framework for the safe, potentially cost saving delivery of not only infliximab but potentially other similar medical infusions at home.

    ARTICLE HIGHLIGHTS

    Research background

    Infliximab is one of the most commonly used biologic therapies in the management of inflammatory bowel disease (IBD). With the development of infliximab biosimilars and resulting reduction in medication cost, its availability and usage worldwide has seen exponential growth for all therapeutic indications.

    Research motivation

    Previous studies have suggested rapid 30 min infliximab infusions to be safe in patients with IBD. Despite this, few centres have moved to deliver infliximab therapy for IBD at a patient’s home and there remains a paucity of literature demonstrating the cost benefit of rapid infliximab infusion compared to standard therapy.

    Research objectives

    The primary aims in this study were to evaluate the safety of transition from standard hospital-based infliximab infusions to rapid infusions and thence to home-based infusions in a protocolised manner, while also assessing efficiency, cost savings and patient satisfaction with this process.

    Research methods

    This retrospective study was conducted across two tertiary IBD centres in Australia. Based on pharmacy prescribing records and historic IBD databases, patients who received infliximab over a 12-year period were identified. Data related to infliximab therapy was retrospectively obtained. Patients that were transitioned to at home infliximab were prospectively surveyed for satisfaction and productivity.

    Research results

    Our study reinforced previous findings in showing that rapid 30 min infliximab was safe in patients IBD with minimal side effects. Furthermore, with careful patient selection patients receiving rapid infusion infliximab were able to be safely transitioned to home based therapy. Rapid infliximab infusions resulted in the halving of time patients spent receiving an infusion and resulted in a 54% reduction in delivery related costs. Patients found the transition to rapid infliximab to be highly satisfying but were neutral about receiving infliximab therapy at home.

    Research conclusions

    In our study, rapid 30 min infliximab infusions appeared to be safe and in a protocolised manner could be delivered safely at home. This process has the ability to substantially reduce costs related to delivery of therapy and provides a viable alternative to under resourced infusion centres in the delivery of infusion therapy.

    Research perspectives

    Rapid Infliximab therapy can be delivered safely at home under the supervision of trained health care staff. Our study provides a framework for other centres to selectively transition patients from traditional infusion centres to alternative destinations such as home based. With further safety studies other infusion therapies could potentially be transitioned safety to be delivered at home at the convenience of the patient.

    猜你喜歡
    大伙
    巨大的回報
    哪里哪里?
    太陽感冒了
    老人的尊嚴
    上海故事(2018年4期)2018-07-09 18:44:58
    改啰唆
    愛你(2017年20期)2017-11-24 16:26:38
    冬天是個調(diào)皮的孩子
    官員講大白話,大伙愛聽
    紅土地(2016年11期)2017-01-15 13:46:36
    腳下生風(fēng)的磊編
    意林(2015年20期)2015-10-21 11:21:08
    生日福利
    趕時間的后果
    解放軍生活(2013年9期)2013-04-29 08:52:02
    日本色播在线视频| 欧美97在线视频| 午夜激情欧美在线| 搡老妇女老女人老熟妇| 国产亚洲最大av| 最近视频中文字幕2019在线8| 少妇裸体淫交视频免费看高清| 久久6这里有精品| 男插女下体视频免费在线播放| 99久久精品国产国产毛片| 非洲黑人性xxxx精品又粗又长| 国产在线一区二区三区精| 国产成人一区二区在线| 久久久午夜欧美精品| 日韩av免费高清视频| 亚洲婷婷狠狠爱综合网| 亚洲av不卡在线观看| 亚洲无线观看免费| 国产视频内射| 人人妻人人澡欧美一区二区| 亚洲av一区综合| 少妇人妻精品综合一区二区| 日韩成人伦理影院| 亚洲精品亚洲一区二区| 又粗又硬又长又爽又黄的视频| 丰满少妇做爰视频| 色尼玛亚洲综合影院| 免费大片黄手机在线观看| 国产黄频视频在线观看| 激情 狠狠 欧美| 狂野欧美白嫩少妇大欣赏| 国产探花在线观看一区二区| 亚洲精品乱码久久久久久按摩| 亚洲自偷自拍三级| 国产亚洲av嫩草精品影院| 亚洲国产精品国产精品| 边亲边吃奶的免费视频| 亚洲一级一片aⅴ在线观看| 嫩草影院入口| 久久久a久久爽久久v久久| 精品不卡国产一区二区三区| 777米奇影视久久| 久久国内精品自在自线图片| 免费人成在线观看视频色| 永久网站在线| 亚洲欧洲日产国产| 熟女人妻精品中文字幕| av专区在线播放| 亚洲精品aⅴ在线观看| 黑人高潮一二区| 一区二区三区乱码不卡18| 亚洲国产精品国产精品| 美女脱内裤让男人舔精品视频| 亚洲伊人久久精品综合| 亚洲高清免费不卡视频| 高清毛片免费看| 女人久久www免费人成看片| av免费观看日本| 国产黄片视频在线免费观看| 色尼玛亚洲综合影院| 国产男女超爽视频在线观看| 五月玫瑰六月丁香| 在线 av 中文字幕| 久久99精品国语久久久| 99久久精品一区二区三区| 一个人观看的视频www高清免费观看| 欧美性感艳星| 美女内射精品一级片tv| 久久久久性生活片| 久久久久久久亚洲中文字幕| 亚洲av二区三区四区| 亚洲自拍偷在线| 国产男人的电影天堂91| 嫩草影院入口| 欧美日韩亚洲高清精品| 天堂av国产一区二区熟女人妻| 欧美日韩一区二区视频在线观看视频在线 | 精品国产三级普通话版| 深爱激情五月婷婷| 日本欧美国产在线视频| 国产精品久久久久久久久免| videos熟女内射| 日韩国内少妇激情av| 国产免费福利视频在线观看| 欧美日韩精品成人综合77777| 免费观看a级毛片全部| 熟妇人妻不卡中文字幕| 午夜激情福利司机影院| 亚洲婷婷狠狠爱综合网| 亚洲精品成人av观看孕妇| 亚洲最大成人手机在线| 一级片'在线观看视频| 欧美性感艳星| 久久久久精品性色| 晚上一个人看的免费电影| 丝袜喷水一区| 老司机影院毛片| 天天躁夜夜躁狠狠久久av| 日本wwww免费看| 成年av动漫网址| 久久精品熟女亚洲av麻豆精品 | 大香蕉97超碰在线| 成人亚洲精品av一区二区| 午夜免费观看性视频| 尤物成人国产欧美一区二区三区| 亚洲欧美成人精品一区二区| 亚洲精品视频女| 久久精品国产自在天天线| 有码 亚洲区| 搡老乐熟女国产| 大香蕉97超碰在线| 久久精品国产亚洲av天美| 欧美高清成人免费视频www| 精品国产露脸久久av麻豆 | 日日撸夜夜添| 一二三四中文在线观看免费高清| 嘟嘟电影网在线观看| 成人综合一区亚洲| 免费看光身美女| 日韩av不卡免费在线播放| 日韩欧美三级三区| av卡一久久| 国产中年淑女户外野战色| 高清在线视频一区二区三区| 成人高潮视频无遮挡免费网站| 黄片wwwwww| 亚洲国产精品sss在线观看| 亚洲国产欧美在线一区| 午夜福利视频精品| 韩国高清视频一区二区三区| 国产激情偷乱视频一区二区| 高清午夜精品一区二区三区| 菩萨蛮人人尽说江南好唐韦庄| 久久久久久久久久黄片| 亚洲国产欧美人成| 老司机影院成人| 色尼玛亚洲综合影院| 亚洲,欧美,日韩| 男的添女的下面高潮视频| 99久久精品热视频| 国产精品一及| 毛片一级片免费看久久久久| 亚洲精品456在线播放app| 少妇的逼水好多| 日本黄大片高清| 草草在线视频免费看| 亚洲av电影在线观看一区二区三区 | 人妻系列 视频| 成人一区二区视频在线观看| 成人毛片60女人毛片免费| 99热网站在线观看| 美女xxoo啪啪120秒动态图| 成年人午夜在线观看视频 | 欧美日韩一区二区视频在线观看视频在线 | 欧美高清成人免费视频www| av在线蜜桃| 亚洲av.av天堂| 91久久精品国产一区二区成人| 三级国产精品片| 秋霞伦理黄片| 91午夜精品亚洲一区二区三区| 国产黄a三级三级三级人| 精品久久久精品久久久| 九九爱精品视频在线观看| 欧美人与善性xxx| 亚洲精品视频女| 亚洲内射少妇av| 国产亚洲精品久久久com| 狠狠精品人妻久久久久久综合| 亚洲精华国产精华液的使用体验| 中文字幕av成人在线电影| 亚洲精品色激情综合| 国产精品久久视频播放| 九九爱精品视频在线观看| 日本熟妇午夜| 免费播放大片免费观看视频在线观看| 欧美成人一区二区免费高清观看| 精品久久久噜噜| 日本-黄色视频高清免费观看| 国产精品福利在线免费观看| a级毛片免费高清观看在线播放| 在线 av 中文字幕| 久久久久久久亚洲中文字幕| 欧美三级亚洲精品| 国产精品一及| 国产真实伦视频高清在线观看| av福利片在线观看| 好男人在线观看高清免费视频| 我要看日韩黄色一级片| 免费不卡的大黄色大毛片视频在线观看 | 婷婷色综合大香蕉| 久久精品人妻少妇| 只有这里有精品99| 18禁在线播放成人免费| 青春草国产在线视频| 免费少妇av软件| 肉色欧美久久久久久久蜜桃 | 国产精品精品国产色婷婷| 精品人妻熟女av久视频| 午夜免费男女啪啪视频观看| 久久久亚洲精品成人影院| 少妇的逼好多水| 亚洲精品日本国产第一区| 国产精品麻豆人妻色哟哟久久 | 成年人午夜在线观看视频 | 日本av手机在线免费观看| 欧美丝袜亚洲另类| 久久久欧美国产精品| 久久久久久九九精品二区国产| 亚洲欧洲日产国产| 久久精品夜色国产| 看黄色毛片网站| 国产精品福利在线免费观看| 女人十人毛片免费观看3o分钟| 99久国产av精品| 日韩,欧美,国产一区二区三区| 免费观看a级毛片全部| 国产av国产精品国产| 精品99又大又爽又粗少妇毛片| 精品酒店卫生间| 精品国产三级普通话版| 亚洲婷婷狠狠爱综合网| 久久精品国产亚洲网站| av在线老鸭窝| 人妻夜夜爽99麻豆av| 嫩草影院新地址| 欧美成人精品欧美一级黄| 黄色一级大片看看| 日日啪夜夜撸| 国产乱人视频| 国产视频内射| 最近2019中文字幕mv第一页| 乱码一卡2卡4卡精品| 久久久久国产网址| 成人毛片a级毛片在线播放| 亚洲欧美精品自产自拍| 美女主播在线视频| av一本久久久久| 国产精品熟女久久久久浪| 亚洲久久久久久中文字幕| 天堂av国产一区二区熟女人妻| 岛国毛片在线播放| 午夜福利在线在线| 亚洲国产av新网站| 男人舔女人下体高潮全视频| 久久人人爽人人爽人人片va| av在线播放精品| 水蜜桃什么品种好| 蜜桃久久精品国产亚洲av| 免费黄色在线免费观看| 免费av观看视频| 亚洲经典国产精华液单| 日本-黄色视频高清免费观看| 男女边摸边吃奶| 街头女战士在线观看网站| 亚洲综合色惰| 久久久精品欧美日韩精品| 国产乱来视频区| 国产成人精品一,二区| 中文天堂在线官网| 美女xxoo啪啪120秒动态图| 免费看日本二区| 一区二区三区高清视频在线| 18禁在线播放成人免费| 干丝袜人妻中文字幕| av天堂中文字幕网| 亚州av有码| 国产精品美女特级片免费视频播放器| 日韩,欧美,国产一区二区三区| 亚洲欧洲日产国产| 18禁裸乳无遮挡免费网站照片| 大又大粗又爽又黄少妇毛片口| 国产乱人视频| 搡老妇女老女人老熟妇| 国产淫语在线视频| 中文天堂在线官网| eeuss影院久久| 午夜福利在线在线| 18禁在线播放成人免费| 日本黄色片子视频| 日韩电影二区| 亚洲欧美精品专区久久| 亚洲av.av天堂| 国产黄色视频一区二区在线观看| 国产免费又黄又爽又色| 久久精品夜夜夜夜夜久久蜜豆| 美女cb高潮喷水在线观看| 精品久久久久久成人av| 自拍偷自拍亚洲精品老妇| 69av精品久久久久久| 欧美成人精品欧美一级黄| 日韩电影二区| 白带黄色成豆腐渣| 白带黄色成豆腐渣| 亚洲自拍偷在线| 国产成人福利小说| 97精品久久久久久久久久精品| 国产综合懂色| 一个人看视频在线观看www免费| 国产av码专区亚洲av| 精品久久久久久久久亚洲| a级毛片免费高清观看在线播放| 亚洲精品成人av观看孕妇| 黄色配什么色好看| av免费在线看不卡| 欧美高清性xxxxhd video| 两个人的视频大全免费| 久久综合国产亚洲精品| 午夜视频国产福利| 久久99热这里只有精品18| av女优亚洲男人天堂| 亚洲国产日韩欧美精品在线观看| 亚洲一级一片aⅴ在线观看| 一二三四中文在线观看免费高清| 久久精品夜色国产| 国产精品久久久久久久久免| 成人高潮视频无遮挡免费网站| 欧美日韩在线观看h| 欧美性感艳星| 一级av片app| 国产精品99久久久久久久久| 欧美日韩在线观看h| 女人十人毛片免费观看3o分钟| 色尼玛亚洲综合影院| 一个人看的www免费观看视频| 亚洲精品自拍成人| 国产成人免费观看mmmm| 成人午夜高清在线视频| 最近的中文字幕免费完整| 久久久久久久久中文| 神马国产精品三级电影在线观看| 国产精品熟女久久久久浪| 欧美日本视频| a级毛片免费高清观看在线播放| 国产久久久一区二区三区| 少妇人妻精品综合一区二区| 99久久精品一区二区三区| 国产成人福利小说| 久久99热这里只频精品6学生| 国产单亲对白刺激| www.av在线官网国产| 26uuu在线亚洲综合色| 少妇猛男粗大的猛烈进出视频 | 夫妻午夜视频| 午夜激情福利司机影院| 特级一级黄色大片| 亚洲av男天堂| 国语对白做爰xxxⅹ性视频网站| 国产伦理片在线播放av一区| 欧美日韩视频高清一区二区三区二| 可以在线观看毛片的网站| av免费在线看不卡| 中文字幕人妻熟人妻熟丝袜美| 日韩伦理黄色片| 麻豆乱淫一区二区| 亚洲精品自拍成人| 久久精品国产亚洲网站| 亚洲精品乱码久久久久久按摩| 亚洲成人久久爱视频| 纵有疾风起免费观看全集完整版 | www.av在线官网国产| 国产黄色小视频在线观看| 人妻一区二区av| 国产精品爽爽va在线观看网站| 欧美变态另类bdsm刘玥| 丰满乱子伦码专区| 午夜免费男女啪啪视频观看| 亚洲av电影在线观看一区二区三区 | 国产久久久一区二区三区| 美女主播在线视频| 亚洲人成网站在线播| 婷婷色综合大香蕉| 九九爱精品视频在线观看| 男女下面进入的视频免费午夜| 欧美成人精品欧美一级黄| 亚洲成人中文字幕在线播放| 成年av动漫网址| 免费播放大片免费观看视频在线观看| 九九爱精品视频在线观看| 成人国产麻豆网| 午夜福利成人在线免费观看| 少妇被粗大猛烈的视频| 欧美 日韩 精品 国产| 亚洲熟女精品中文字幕| 亚洲av电影不卡..在线观看| 搡女人真爽免费视频火全软件| 精品99又大又爽又粗少妇毛片| 在线观看一区二区三区| 久久久久久久久久久丰满| 又大又黄又爽视频免费| 日日啪夜夜爽| 精品一区二区免费观看| 国产综合懂色| 日韩av免费高清视频| 欧美潮喷喷水| 欧美性猛交╳xxx乱大交人| 日韩成人伦理影院| 亚洲精品久久午夜乱码| 成人亚洲精品一区在线观看 | 久久久成人免费电影| 亚洲精品一区蜜桃| 美女黄网站色视频| 日韩电影二区| 嫩草影院精品99| 国产伦在线观看视频一区| 少妇裸体淫交视频免费看高清| 久久精品国产亚洲av涩爱| 一级毛片久久久久久久久女| 伦理电影大哥的女人| 大片免费播放器 马上看| 免费无遮挡裸体视频| 一区二区三区免费毛片| 日本黄大片高清| 成人性生交大片免费视频hd| 婷婷色麻豆天堂久久| 国产亚洲一区二区精品| 欧美bdsm另类| av黄色大香蕉| 少妇的逼好多水| 少妇的逼水好多| 一级二级三级毛片免费看| 日日摸夜夜添夜夜添av毛片| av在线播放精品| 国产精品一区二区三区四区免费观看| 大片免费播放器 马上看| 99视频精品全部免费 在线| 午夜福利视频1000在线观看| 日韩欧美 国产精品| 国产人妻一区二区三区在| 亚洲精品视频女| 久久人人爽人人片av| 深夜a级毛片| 女人被狂操c到高潮| 日韩欧美精品v在线| 中文字幕亚洲精品专区| 亚洲国产精品专区欧美| 国产在视频线在精品| 久久久久久久久久黄片| 80岁老熟妇乱子伦牲交| 日韩成人av中文字幕在线观看| 精品酒店卫生间| 18禁在线无遮挡免费观看视频| 国产熟女欧美一区二区| 精品一区二区三区视频在线| 女人久久www免费人成看片| 搡女人真爽免费视频火全软件| 少妇被粗大猛烈的视频| 亚洲综合精品二区| 小蜜桃在线观看免费完整版高清| 在线观看av片永久免费下载| 成人午夜高清在线视频| 中文字幕久久专区| 最新中文字幕久久久久| 国产成人aa在线观看| www.av在线官网国产| 亚洲欧美日韩卡通动漫| 你懂的网址亚洲精品在线观看| 国产单亲对白刺激| 五月伊人婷婷丁香| 国产 一区 欧美 日韩| 国产亚洲91精品色在线| 国产精品人妻久久久久久| 91在线精品国自产拍蜜月| 国产男女超爽视频在线观看| 99久国产av精品国产电影| 国产精品综合久久久久久久免费| 成年免费大片在线观看| 亚洲美女视频黄频| 欧美97在线视频| 青春草亚洲视频在线观看| 一个人看视频在线观看www免费| 亚洲精品影视一区二区三区av| 欧美日本视频| 国产成人91sexporn| 亚洲国产欧美在线一区| 一级黄片播放器| 欧美日韩综合久久久久久| 国产成人福利小说| 欧美性猛交╳xxx乱大交人| 伊人久久国产一区二区| 亚洲精品,欧美精品| 久久久久精品性色| 成年女人看的毛片在线观看| av卡一久久| 国产成人精品福利久久| 偷拍熟女少妇极品色| 精品国内亚洲2022精品成人| www.色视频.com| 精品99又大又爽又粗少妇毛片| 日本与韩国留学比较| 最近2019中文字幕mv第一页| 大话2 男鬼变身卡| 国产亚洲av嫩草精品影院| 精品不卡国产一区二区三区| 亚洲精品影视一区二区三区av| 十八禁网站网址无遮挡 | 大话2 男鬼变身卡| 国产国拍精品亚洲av在线观看| 亚洲一区高清亚洲精品| 亚洲色图av天堂| 乱人视频在线观看| 国产伦精品一区二区三区四那| 99久久精品热视频| 亚洲国产色片| 三级经典国产精品| 精品午夜福利在线看| 国产视频内射| 人体艺术视频欧美日本| 性插视频无遮挡在线免费观看| 成人综合一区亚洲| 国产伦精品一区二区三区视频9| 亚洲人成网站在线播| 精品久久久久久电影网| 免费黄频网站在线观看国产| 亚州av有码| 成人欧美大片| 国产精品精品国产色婷婷| 99久久精品一区二区三区| 免费不卡的大黄色大毛片视频在线观看 | 成人鲁丝片一二三区免费| 国产高潮美女av| 国产老妇伦熟女老妇高清| 亚洲av日韩在线播放| 精品一区二区三区视频在线| 欧美xxⅹ黑人| 午夜福利视频1000在线观看| 久久鲁丝午夜福利片| 国产成人福利小说| 亚洲在线观看片| 2022亚洲国产成人精品| 成年人午夜在线观看视频 | 国产一区二区在线观看日韩| 女人被狂操c到高潮| 汤姆久久久久久久影院中文字幕 | 色网站视频免费| 少妇人妻精品综合一区二区| 久久精品夜夜夜夜夜久久蜜豆| 久久这里有精品视频免费| 久久6这里有精品| 永久免费av网站大全| 亚洲国产成人一精品久久久| 天堂√8在线中文| 亚洲最大成人中文| 国产精品嫩草影院av在线观看| 街头女战士在线观看网站| 天堂影院成人在线观看| 久久久精品94久久精品| 老司机影院毛片| 99热6这里只有精品| 亚洲怡红院男人天堂| 久久久久久久久中文| 国产精品久久久久久av不卡| 亚洲av中文av极速乱| 久久精品国产鲁丝片午夜精品| 国产精品一及| 国产在视频线在精品| 日韩欧美三级三区| 熟妇人妻久久中文字幕3abv| 一本一本综合久久| 日韩伦理黄色片| a级一级毛片免费在线观看| 女人十人毛片免费观看3o分钟| 国产爱豆传媒在线观看| 亚洲不卡免费看| 国产精品三级大全| 三级男女做爰猛烈吃奶摸视频| 韩国av在线不卡| 免费不卡的大黄色大毛片视频在线观看 | 日韩三级伦理在线观看| 精品少妇黑人巨大在线播放| 中文乱码字字幕精品一区二区三区 | 国产黄a三级三级三级人| 成人一区二区视频在线观看| xxx大片免费视频| 亚洲三级黄色毛片| 高清日韩中文字幕在线| 免费少妇av软件| 丰满乱子伦码专区| av在线亚洲专区| 麻豆国产97在线/欧美| 日韩一区二区视频免费看| 夫妻午夜视频| 国产淫语在线视频| h日本视频在线播放| 精品久久久久久电影网| 亚洲av成人精品一二三区| 韩国高清视频一区二区三区| 亚洲精品日韩在线中文字幕| 成人性生交大片免费视频hd| 成人毛片a级毛片在线播放| 日韩伦理黄色片| 成人鲁丝片一二三区免费| 街头女战士在线观看网站| 国产精品伦人一区二区| 日韩av在线免费看完整版不卡| 午夜福利视频1000在线观看| 欧美日韩一区二区视频在线观看视频在线 | 国产成人a∨麻豆精品| 网址你懂的国产日韩在线| 久久久久九九精品影院| av在线蜜桃| 国产乱来视频区| 久久精品久久久久久噜噜老黄| 99久久人妻综合| 亚洲国产欧美人成| 欧美激情国产日韩精品一区| 午夜福利视频精品| 2022亚洲国产成人精品| 午夜精品一区二区三区免费看| 91精品伊人久久大香线蕉| 国产精品福利在线免费观看| 中文字幕久久专区| 国产精品久久视频播放| 亚洲欧美日韩无卡精品| 国产激情偷乱视频一区二区|